WARRIOR

March 15, 2019

Women’s Ischemia Trial to Reduce Events in Non-Obstructive CAD (WARRIOR)

  • Clinical Trial Information

    Trial Contact: Noel, Henry; Tinetti, Meghan; Peisner, Pamela

  • IRB No: S18.133.09

    Protocol Abbrev: WARRIOR

    Principal Investigator: Arnold M. Einhorn, MD

    Age Group: Adult

    Secondary Protocol No: Version Number: 6.0

    Treatment: Drug: High dose potent statin The IMT-assigned women will receive high-dose, potent statin (atorvastatin 40-80 mg/d or rosuvastatin 20-40mg) class of lipid-lowering medications. Other Name: atorvastatin or rosuvastatin Drug: ACE-I (lisinopril) or ARB (losartan) Angiotensin converting enzyme inhibitors (ACE inhibitors) and angiotensin receptor blockers (ARBs) are widely prescribed for primary hypertension. Other Name: ACE-I or ARB Drug: Aspirin Will be recommended to IMT women without contraindications or bleeding risk.

    Therapies Involved: Medication

    ClinicalTrials.gov ID: NCT03417388

  • Objective

    The primary outcome is MACE, defined as first occurrence of all-cause death, non- fatal MI, non-fatal stroke, or hospitalization for angina or HF.

  • Key Eligibility

    •   Signs and symptoms of suspected ischemia prompting referral for further evaluation by cardiac catheterization, or coronary angiogram or coronary CT angiogram.
    •   Willing to provide written informed consent.
    •   Age ≥18 yrs.
    •   Non-obstructive CAD defined as <50% diameter reduction of a major epicardial vessel.